0001209191-16-095840.txt : 20160204 0001209191-16-095840.hdr.sgml : 20160204 20160204185122 ACCESSION NUMBER: 0001209191-16-095840 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160202 FILED AS OF DATE: 20160204 DATE AS OF CHANGE: 20160204 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 161389820 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2016-02-02 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2016-02-02 4 A 0 17299 0.01 A 121763 D Common Stock 2016-02-03 4 S 0 2597 89.92 D 119166 D Common Stock 2016-02-03 4 S 0 2100 90.98 D 117066 D Common Stock 2016-02-03 4 S 0 700 91.89 D 116366 D Common Stock 2016-02-03 4 S 0 645 92.80 D 115721 D Common Stock 140 I 401(k) Stock Option (Right to Buy) 91.05 2016-02-02 4 A 0 34482 0.00 A 2026-02-01 Common Stock 34482 34482 D Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $89.92 (range $89.31 to $90.27). Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $90.98 (range $90.38 to $91.32). Open market sales reported on this line occurred at a weighted average price of $91.89 (range $91.38 to $92.35). Open market sales reported on this line occurred at a weighted average price of $92.80 (range $92.40 to $93.03). The option vests in 16 quarterly installments from 02/02/2016. Omar White, Attorney-In-Fact 2016-02-04